Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo nodularis and atopic dermatitis, respectively Galderma will also host a symposium an




